US government funding yielded hundreds of patents for China-based researchers
Data shows U.S. government funding behind 1,020 patents for China-based inventors
Critics argue China unfairly benefits in fields like biotechnology and semiconductors
Data fans controversy around US-China science pact
Adds Chinese government comment in paragraphs 11, 12
By Michael Martina
WASHINGTON, Aug 29 (Reuters) -The U.S. Defense Department, NASA and other government agencies funded research that led to more than 1,000 U.S. patents for China-based inventors since 2010, including in sensitive fields such as biotechnology and semiconductors, data from the U.S. patent agency showed.
The U.S. patent data, which was reviewed by Reuters and has not been reported previously, will amplify calls to cancel or renegotiate the landmark U.S.-China Science and Technology Agreement, a cooperation deal that critics say disproportionately benefits Washington's top geopolitical rival.
The U.S. Patent and Trademark Office supplied the data this month to the House of Representatives' select committee on China. In June, it asked the agency whether U.S. funding resulted in Chinese breakthroughs, aiming to highlight what it views as the risks of renewing the pact.
According to the patent office, the agency granted 1,020 patents from 2010 through the first quarter of 2024 that were both funded at least in part by the U.S. government and involved at least one China-residing inventor. The data does not detail whether U.S. entities or individuals share the patents.
The patents included 197 in pharmaceuticals and 154 in biotechnology, both strategic industries for China and the United States.
Funding from various U.S. government agencies supported the research, leading to 92 patents through Pentagon funding, 175 from Department of Energy money and four from NASA financial support. The U.S. space agency faces prohibitions under U.S. law from cooperating with China or Chinese companies.
Funding from the Department of Health and Human Services yielded 356 such patents, the most of any agency.
"It's alarming that U.S. taxpayers have unwittingly funded over 1,000 patents claimed by Chinese entities, with the Department of Defense accounting for nearly 100 of these patents," the select committee's chairman, Republican Representative John Moolenaar, said in an email to Reuters.
The patent office, NASA and the departments of defense, energy and health did not respond to requests for comment.
The State Department, which is responsible for renegotiating the China agreement, said it remains in communication with China about the accord. "The United States remains committed to advancing and protecting U.S. interests in science and technology," a department spokesperson said.
Liu Pengyu, a spokesperson for China's embassy in Washington, said science and technology was an "open business."
"We hope that some officials in the U.S. will abandon the Cold War mentality," Liu said.
The data provided by the patent authority to the House committee in a letter dated Aug. 14 did not disclose specific projects or patents. There was no indication that the funding was the direct result of the agreement, which after its signing in 1979 laid the foundation for a boom in U.S.-China academic and commercial exchanges.
The patents covered advances in fields including semiconductors, molecular chemistry and polymers, chemical engineering, nanotechnology and medical technology.
Such patents dropped from an annual high in 2019 of 99, to 61 in 2023. In 2024, 16 were recorded in the first quarter despite heightened U.S. government concern that Chinese science and technology advances present a national security threat.
POSSIBLE EXTENSION OF CHINA PACT
Once hailed as a stabilizing force in U.S.-China relations, the cooperation agreement has come under fire from lawmakers concerned about Beijing's growing military power and alleged theft of U.S. intellectual property.
Proponents of renewing the deal argue that ending it would stifle academic and commercial cooperation and prevent the U.S. from learning about China's technical advances.
A second six-month extension to the agreement, which expired in August 2023, ended on Tuesday. Another short-term extension could occur in the coming days as both sides have sought to renegotiate its terms.
The patents identified by the U.S. patent office represent a small fraction of China's global patents. Patents grant exclusive legal rights to inventors but also publicly disclose technical information about those inventions.
In one measure of global innovation, China has in recent years surpassed the U.S. to become the world's leading filer of patent applications.
Reporting by Michael Martina; Editing by Don Durfee and Cynthia Osterman
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
